Biologic therapy in HS shows dual benefits: improved skin lesions and potential systemic anti-inflammatory effects, as indicated by lipid profile changes. Early treatment initiation is crucial for ...

Amtagvi shows a 48.8% ORR in advanced melanoma, with higher efficacy in less heavily treated patients. FDA granted accelerated approval for Amtagvi in 2024 for unresectable or metastatic melanoma ...

Tirzepatide produced significant weight loss, reduced insulin requirements, and improved glucose control without increasing hypoglycemia when used off-label in adults with type 1 diabetes (T1D), new ...

In this episode we are joined by Eric Fontana, VP of Client Solutions at Optum Life Sciences; Bethany Kalich, U.S. Medical Director, Cardiovascular at Amgen; and Christen Buseman, Director, IDN ...

Benign prostatic hyperplasia (BPH) is one of the most common urologic conditions affecting men as they age, with nearly 50% of men over 50 experiencing symptoms. Despite its prevalence, treatment ...

Reversing the standard approved dose levels of nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic melanoma led to less ...

Real-world data show that the GLP-1 receptor agonists semaglutide and tirzepatide not only manage blood sugar and weight but also mirror their heart-protective effects from clinical trials in everyday ...

The European Medicines Agency (EMA) uses Data Analysis and Real-World Interrogation Network (DARWIN EU), a data network that became fully operational in 2024, to generate real-world evidence on ...

Digital patient profiles and real-world data enhance oncology trial design, patient recruitment, and reduce trial failure risks. Phesi's platform aligns trial designs with real-world data, minimizing ...